BTCUSD: If history repeats itself2019 fractal to scale with similarities so far. $25K needs to break for bull-flag confirmation. $30K needs to break for +80% upside target to ~$50K.
2019
Novavax Surge Over 130% On $1.4 Bln Covid Shot Deal with SanofiNovavax shares ( NASDAQ:NVAX ) surged over 130% after a $1.4 billion deal with Sanofi was announced to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid. The biotech firm announced a licensing agreement with Sanofi to sell Novavax’s Covid vaccine worldwide, with Sanofi paying Novavax $500 million upfront and future payments up to $700 million based on other milestones, in addition to royalties.
Sanofi will receive a sole license to develop and commercialize a combination flu and Covid vaccine containing Novavax’s Covid shot and Sanofi’s flu shot. Novavax ( NASDAQ:NVAX ) is also entitled to launch and sales milestones of up to $200 million for any vaccine developed by Sanofi as part of the deal. The company expects to launch a late-stage trial of its own combination vaccine targeting Covid and the flu and a stand-alone flu shot later this year.
The licensing agreement will likely lift Novavax’s “going concern” warning issued last year, after the company said “substantial doubt exists” to continue operating. A significant uptick for Novavax ( NASDAQ:NVAX ) shares follows yearslong financial woes for the biotech firm. The company cut its 2024 sales forecast in its first-quarter review, decreasing projections from between $800 million and $1 billion to $400 million to $600 million. Novavax ( NASDAQ:NVAX ) also reported a first-quarter net loss of $148 million, compared with a net loss of $294 million during the same period last year.
As part of the deal, Sanofi is also taking a less than 5% equity stake in Novavax, and Novavax ( NASDAQ:NVAX ) will receive royalty payments for future sales of its COVID-19 vaccine and the future combination COVID-19 and flu vaccine. The deal will allow Novavax to lift its “going concern” warning, which was issued in early 2023 over concerns that it may not be able to financially survive as demand for COVID-19 vaccines waned.
Alongside the Sanofi deal, Novavax ( NASDAQ:NVAX ) also reported first-quarter results that missed analyst estimates. Novavax ( NASDAQ:NVAX ) reported revenue for the first quarter of $93.9 million, shy of the $101.3 million analysts expected, and posted a loss of $147.6 million, or $1.05 per share, wider than the loss of $127.4 million, or 90 cents per share, that analysts projected.
For the full fiscal year, Novavax ( NASDAQ:NVAX ) lowered its projected revenue to $400 million to $600 million, down from the previous range of $800 million to $1 billion. However, the estimated $570 million the company expects to receive from Sanofi this year pushed its combined revenue and payments projections higher, to $970 million to $1.17 billion.
Technical Outlook
Novavax ( NASDAQ:NVAX ) is up 98% as of the time of writing, trading above the 200-day Moving Average (MA). The stock has a Relative Strength Index (RSI) of 86.66 which is clearly in an overbought territory. The daily price charts depict an upside or upward gap that occurred as a result of the impending deal.
bitcoin MAP Bitcoin
Digital cash system and associated currency
Bitcoin is the first decentralized cryptocurrency. Nodes in the peer-to-peer bitcoin network verify transactions through cryptography and record them in a public distributed ledger, called a blockchain, without central oversight. Consensus between nodes is achieved using a computationally intensive system based on proof-of-work called mining
AZN - BEARISH SCENARIOAstraZeneca's stock experienced a significant decline of over 4% on Monday due to uncertainties surrounding the future of CEO Pascal Soriot, as reported in the news. Initially, the company refrained from commenting on the report but later clarified that they do not engage in discussions regarding market rumors. Their shares, listed as NASDAQ: AZN, closed down 3.2%, marking the lowest point since July 19. Market analysts and a shareholder attributed this decline to the report, which indicated the possibility of Soriot leaving as soon as next year. Additionally, another article published on the same day discussed the retirement of Mene Pangalos, the long-time head of biopharmaceuticals research at AstraZeneca, although it appeared to present a contradictory view, quoting Pangalos as stating that Soriot had many productive years ahead of him.
This supports potential competition of head and shoulder formation to the mid-50s range.
2023 looks awfully similar to 2019, I am Long here. I copy pasted the previous cycle chart and it literally looks like a copy. I am long here, I have confidence that we will definitely not go below 20k. The indicators are also the same, with 1D close to resetting; I expect us to top out at 35k around May 2023.
S&P 500 Overview and Investment OpportunityDuring Covid-19, the market significantly dropped in price. Post this retracement, the market recovered swiftly. With many indicators such as inverted treasury yields pointing towards an impending recession, we form the following view on the S&P500.
We envisage the market to drop significantly during the coming months and see the marked investment zone is a good mid term opportunity. We are monitoring these movements and will continue to keep the market updated.
This analysis also correlates to other major indices such as Nasdaq, Dow Jones and others such as the Ftse100.
Wishing all of you a successful New Year. This year will bring ample opportunities for the patient and observant. Stay tuned for more!
Nifty Analysis in the Shadow of Covid SituationsNifty Analysis in the Shadow of Covid Situations in India and China and world over. How Nifty has been behaving with fears of new wave of Covid situations in India.
Novavax NVAX Accumulation or distribution? Wychoff wants to know! Phase C, Spring Stage? M.Cap is below CASH, Best in Class vaccine with over 43+ International Approvals.
It’s just amazing what Nova’s teams have be able to accomplish(for its size) around the globe!
MRNA short sale$MRNA Joe Biden says the COVID-19 pandemic is over. After breakdown 140 zone , now we ca go to 115 lvl june lows, #doublebottom #markets #stocks $SPX
NVAX… once a loser always a loserthe inability of NVAX to properly capitalize on the covid vaccine is a sign of a poorly managed company. was the rise from near penny status exceptional? of course. was the following wealth destruction of epic proportions? sure was.
endless upset longs continue to exit as all good news acts as a selling event. this will be a ride back to single digits for a company who, pre-covid, could not get a single ball across the goal line.
COVID-19 Double Bottom Buy For EUR/USDWe have a long-term weekly EUR/USD double bottom on the horizon. Although it’s more than a 100 pips off, it never hurts to be prepared:
COVID-19 Double Bottom, 1.0635-37
Here's the trade:
1) Buy 1.0655
2) Initial Stop Loss @ 1.0594
3) 1:1 Risk vs Reward, Profit Target @ 1.0716
GBPAUD - SIGN OF REVERSAL? hello traders,
as we see it's counterpart - gold - losing steam,
we can see a turn-around in pound aussie pair.
also usd bullish strength will help this pair.
we also see economic news for aussie - rba meeting minutes which can impact this pair.
mar 14th - 20th aiming for $1.81 or above.
OANDA:GBPAUD
Rejected again from descending triangle, like 2019 and 2018. Neutral. I just see a possible scenario. I hope we break the trend line and move to 72k.
It's still early too say, but we still not break any resistance yet.
I just think this choppiness is to completely kill leveraged traders from both sides before the take the plunge to 19k.
Repeat of the 2019 bullrunMaybe a repeat of the 2019 bullrun?
That would mean the 4-year cycle can be kind of correct when counting from bottom to bottom.
The bear could be a few months shorter than 2014 & 2018.
HLT is coming below $120 within a short time!Technical Reason:
1. Failed to break $160 ( three times)
2. RSI strong negative divergence.
3. Elliot Wave Complete
4.fibonacci 161% is at around $115 level
Fundamental Reason:
1. Long-term Covid effects in this industry
2. Higher Inflation. Increasing oil prices will further hit the industry negatively!
3. Company's debt is very high, lower operating margin. Net Asset Value is negative!
4. Further more, if war between Russia and Ukraine starts, inflation will further increase and travel-tourism industry will be the worst sufferer! Many companies might be bankrupted!
BTC LIGHTS OUT, SUB 30KThis idea leans a bit more on speculation, but it is something that's crossed my mind recently.
Given the IMF practicing for cyber-attacks specifically aimed at the global financial system, it gives worry of a covid like crash that'll break support at 30k.
Not to mention how close the current price action is now resembling the price action of back in March 2020. Take a look at the trend line on the chart image below:
It is the single most important trend line to hold in order to ensure that the bull run continues . The same goes for the PoC, sitting around 46k. If we break it along w/ the white trendline, it's a wrap. BBWP indicator has confirmed the end of consolidation moving into volatility... that I believe will head to sub 30k levels.
Key lines of support and resistance are identical to the previous idea linked below.
The likelihood of this entire idea playing out to be invalidated would be if we break above the prev high near 52K.
Rip Grichka Bogdanoff, may your phone calls ring beyond the grave .
INDIA COVID Wave incoming Update II Previously (see linked idea), the MACD model projected " a new wave should be approaching and happening in India in December 2021, going into 2022."
This was back in October 20, 2021
Just started as expected! Seen that the last week of 2021 and first week in 2022 is registering a spike, and a greater spike following.
Albeit the spike is not as pronounced yet, but expected as now we have Omicron. Back in October 20 at time of posting, Omicron was not yet identified. It was only made known in early December 2021.
Another example PROOF that the projection model works!
Going forward, it appears that serious acceleration of the spread should start end January and once February turns round.
Covid becomes our friend - 2021 wrap upDear all,
It's time to wrap up 2021 and outline what has happened based on an analysis of S&P500 as a major index.
At first glance (and as the title suggests) covid stayed with us throughout the whole year causing volatility in the market. Average correction caused by C19 and its new variants equaled 4.95%, with the biggest decrease of 5.7% caused by the Delta strain. Overall the S&P500 returned close to 30% which taking all the worrying events into account gives an excellent result. When it comes to non-C19 events, Evergrande problem
Now, as we less outlined major events of 2021 (regarding us500) let's cover a short prediction of what may/ may not happen in 2022. Without any doubt, 2022 will be exceptionally interesting. Firstly, we will experience already announced tapering, which is supposed to end by summer 2022. Secondly, the current (i.e. 4th) wave of C19 caused by the Omicron variant is widely believed to be the last one as the kids have been infected. Moreover, at the beginning of 2022 (what we can already see) 3 billion people are said to be infected including many. This fact may suggest a pullback from record highs and more corrections caused by C19. However, on the other hand, as a vast number of people will get infected, they will build global resistance and thus a bad environment for C19 to develop new variants, not to mention medicines produced by Pfizer, etc. Worth mention is also rising tension between Russia and Ukraine, where the former one is expected to attract Jan/Feb. These possible initial events will shed a light on the rest of the year. Diversification and liquidity (including differentiation) seem to be the key to uncertainty and thus volatility on the market in 2022.
Disclaimer!
This post does not provide financial advice. Always do your own analysis. Be aware that only you are responsible for your trades. Trade safe and keep in mind the risk!
ARDS Covid-19 First-in-Class Antibody | +818% Analyst Rating ! Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 32.605Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
Happy New Year!
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections.
- Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
$IINN PT 9 and higherInspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Moderna about to reclaim bullish Channel. Short-Term-BULLISH! Not financial advice!
With the new corona variant spreading fear all over the world, PFE and MRNA are running. I think it's possible for MRNA to reclaim the bullish channel, aka the Bull-Trap that broke down, when PFE announced the Paxlovid-med. I got in MRNA way to late, now taking a risky trade, since MRNA gaps like crazy, and there's always the chance that it'll brake down to be traded at skipped price-levels. I think one should watch out for PFE announcing Paxlovid being effective against the omicron variant, which could lead a lot of investors to switch to PFE.
Today I want to see MRNA reclaiming the bullish channel at $377,xx and hold within this channel.
From there on, it's more than a 30% ride to the top of the channel. But this stock has done crazy things like this in the past. Depending on how fast MRNA manages to reclaim the top, the price correlates with the last ATH at $494,xx. I think, if it manages to get back at the center of the channel, it will be rejected at the old resistance at $463,xx first, settle a bit and then trying to break the $500. My plan is to sell at $463 and then watch how things develop.
But remember if, you're not in it by now, it maybe is bad timing to get in at this pricelevel. Risk is way to high, because of the gaps. That is why I marked this trading strategy as Neutral.
Good luck in the markets!
Again, this is not financial advice!
